Abstract Lysine‐specific demethylase 1 (LSD1) is a flavin adenine dinucleotide (FAD)
dependent monoamine oxidase (MAO) that erases the mono‐, and dimethylation of histone …

Background Prostate cancer is among prevalent cancers in men. Numerous strategies have
been proposed to intervene with the important prostate cancer-related signaling pathways …

Background Combining an immune checkpoint inhibitor with a tumor vaccine may modulate
the immune system to leverage complementary mechanisms of action that lead to sustained …

The targeted regulation of LSD1, which is highly expressed in a variety of tumor cells, is a
promising cancer therapy strategy. Several LSD1 inhibitors are currently under clinical …

Enhancers are cis-acting elements with many sites bound by transcription factors and
activate transcription over long distance. Histone modifications are critical for enhancer …

Modulation of histone methylation status is regarded as an important mechanism of
epigenetic regulation and has substantial clinical potential for the therapy of diseases …

Epigenetics has emerged as a prime focus area in the field of cancer research. Lysine-
specific demethylase 1A (LSD1), the first discovered histone demethylase, is mainly …

Endometrial cancer (EC) often exhibit aberrant activation of PI3K/Akt/mTOR signaling and
targeted therapies using mTOR inhibitors showed limited success. The epigenetic modifier …

During the last decades, male urogenital cancers (including prostate, renal, bladder and
testicular cancers) have become one of the most frequently encountered malignancies …

Abstract Background Circular RNAs (circRNAs) constitute a largely unexplored source for
biomarker discovery in prostate cancer (PC). Here, we characterize the biomarker potential …